地舒单抗的药物依从性与治疗时长对髋部骨折患者死亡风险的影响
本研究利用台湾全民健康保险研究数据库2008至2019年数据,纳入21,316例骨质疏松性髋部骨折术后使用地舒单抗的患者,评估药物依从性和治疗时长与死亡风险的关系。结果显示,地舒单抗用药间隔≤7个月及治疗超过1、2、3年与较低的全因死亡风险相关,良好依从性和较长疗程还与癌症及心血管疾病死亡风险降低相关。
要点
- 地舒单抗用药间隔≤7个月较>7个月与较低全因死亡风险相关(HR 0.60,95%CI 0.57~0.64)。
- 治疗超过1、2、3年较不足1年与较低全因死亡风险相关(HR分别为0.68、0.48、0.29)。
- 良好依从性和较长疗程还与癌症及心血管疾病死亡风险降低相关。
核心结论
- 更好的药物依从性和更长的地舒单抗治疗时长与髋部骨折术后患者较低的全因死亡风险相关。
- 研究强调了地舒单抗适当给药时间间隔的益处,这些发现为骨质疏松性髋部骨折的管理提供了重要见解,并可能为临床实践和指南制定提供信息。
研究设计与样本
- 队列研究,使用台湾全民健康保险研究数据库(NHIRD)的全国人群数据。
- 纳入2008年至2019年间新诊断为骨质疏松和髋部骨折、术后使用地舒单抗的患者,共21,316例。
主要发现
- 与地舒单抗用药间隔>7个月相比,间隔≤7个月的全因死亡风险较低(HR 0.60,95%CI 0.57~0.64)。
- 地舒单抗治疗超过1年、2年、3年的患者较治疗不足1年者全因死亡风险更低(HR分别为0.68(95%CI 0.64~0.73)、0.48(95%CI 0.43~0.53)、0.29(95%CI 0.26~0.33))。
- 排除短期死亡后的分析结果相似。
- 死因分析显示,良好依从性和较长疗程与癌症及心血管疾病死亡风险降低相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: This study aimed to assess the impact of drug adherence and treatment duration for denosumab on mortality risk after hip fracture surgery. Lower all-cause mortality risk was associated with drug intervals of 7 months or less and longer treatment duration. The study highlights the importance of proper denosumab administration. PURPOSE: Prescription of anti-osteoporotic medications (AOMs) after osteoporotic hip fracture may increase bone mineral density (BMD) and decrease mortality risk. However, few studies have been conducted on drug adherence and treatment duration for denosumab, a popular choice among AOMs. This study aimed to assess the impact of denosumab adherence and treatment duration on the mortality risk of hip fracture patients after surgery. METHODS: We conducted a cohort study using nationwide population data from National Health Insurance Research Database (NHIRD) in Taiwan. Patients newly diagnosed with osteoporosis and hip fracture between 2008 and 2019 who used denosumab after surgery were included. We assessed drug adherence, treatment duration, and other parameters associated with patient outcomes. RESULTS: A total of 21,316 patients diagnosed with osteoporotic hip fractures were included. Compared with a > 7-month drug interval for denosumab, an interval of ≤ 7 months led to lower all-cause mortality risk (hazard ratio (HR): 0.60, 95% confidence interval (CI): 0.57 ~ 0.64). Patients with denosumab treatment for over 1, 2, and 3 years had lower all-cause mortality risk (HR&CI: 0.68 (0.64 ~ 0.73), 0.48 (0.43 ~ 0.53), 0.29 (0.26 ~ 0.33)) than those with treatment duration < 1 year. Analysis after excluding short-term death yielded similar results. Analysis of causes of death also showed that good adherence and longer duration were associated with reduced mortality due to cancer and cardiovascular disease. CONCLUSION: Better drug adherence and longer duration of denosumab treatment are associated with lower all-cause mortality risk among hip fracture patients after surgery. Our study highlights the benefits of a proper time interval of denosumab administration. These findings provide important insight into management of osteoporotic hip fractures and may inform clinical practice and development of guidelines.
引用
- Tsai YL, Wu CH, Li CC, et al. Drug adherence and treatment duration for denosumab and mortality risk among hip fracture patients. Osteoporos Int. 2023. PMID: 37466659. doi:10.1007/s00198-023-06845-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。